Development and Clinical Application of a Real-World Population Pharmacokinetic Model of Rivaroxaban in Asian Patients with Atrial Fibrillation
Nian-Shiuan Lai, Chun-Jung Lin, Ching-Hua Kuo, Yu-Fong Peng, Sung-Chun Tang, Chih-Fen Huang, Shin-Yi Lin, Shu-Wen Lin · 2026
Read Development and Clinical Application of a Real-World Population Pharmacokinetic Model of Rivaroxaban in Asian Patients with Atrial Fibrillation by Nian-Shiuan Lai, Chun-Jung Lin, Ching-Hua Kuo, Yu-Fong Peng, Sung-Chun Tang, Chih-Fen Huang, Shin-Yi Lin, Shu-Wen Lin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13272223.txt.
Description
Nian-Shiuan Lai and colleagues built a drug level model in 2026 for Asian heart patients. The drug is rivaroxaban, a blood thinner that prevents stroke. Patients took it for an irregular heart rhythm. Blood levels vary widely between people on the same dose. The team measured levels in a real-world patient cohort. Hundreds of samples came from over two hundred patients. A separate cohort tested the model. Outcomes included clots and major bleeding events.
A simple one-compartment model described the drug well. Kidney function strongly shaped how fast it cleared. Certain interacting drugs also slowed clearance. Lean body weight shaped its spread through the body. Outside tests predicted levels accurately. Low resting levels tended to track with clot events. High resting levels tended to track with bleeding. The authors offer the model as a practical clinic tool. It can flag patients at risk from standard doses.
Catalog record
| CREATOR | Nian-Shiuan Lai, Chun-Jung Lin, Ching-Hua Kuo, Yu-Fong Peng, Sung-Chun Tang, Chih-Fen Huang, Shin-Yi Lin, Shu-Wen Lin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |